{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:36:38Z","timestamp":1791333398502,"version":"4.3.1"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.eplepsyres.2021.106806","type":"journal-article","created":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T02:57:08Z","timestamp":1635821828000},"page":"106806","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Evaluation of levocarnitine, lactulose, and combination therapy for the treatment of valproic acid-induced hyperammonemia in critically ill patients"],"prefix":"10.1016","volume":"178","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6565-5241","authenticated-orcid":false,"given":"Carli","family":"Nicholson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0602-820X","authenticated-orcid":false,"given":"Melissa","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4235-4547","authenticated-orcid":false,"given":"Chanda","family":"Mullen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9034-8996","authenticated-orcid":false,"given":"Brittany","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2021.106806_bib1","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jhep.2010.11.031","article-title":"New insights on the metabolism of valproate-induced hyperammonemia: inhibition of hepatic N-acetylglutamate synthase activity by valproyl-CoA","volume":"55","author":"Aires","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.eplepsyres.2021.106806_bib2","article-title":"Valproic acid induced hyperammonemia in a long time treated patient","volume":"2016","author":"Aiyer","year":"2016","journal-title":"Case Rep. Psychiatr."},{"issue":"2","key":"10.1016\/j.eplepsyres.2021.106806_bib3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.9740\/mhc.2018.03.073","article-title":"Valproic acid-induced hyperammonemia: incidence, clinical significance, and treatment management","volume":"8","author":"Baddour","year":"2018","journal-title":"Ment. Health Clin."},{"issue":"3","key":"10.1016\/j.eplepsyres.2021.106806_bib4","doi-asserted-by":"crossref","first-page":"148","DOI":"10.9740\/mhc.2018.05.148","article-title":"Levocarnitine for valproate-induced hyperammonemia in the psychiatric setting: a case series and literature review","volume":"8","author":"Brown","year":"2018","journal-title":"Ment. Health Clin."},{"key":"10.1016\/j.eplepsyres.2021.106806_bib5","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.genhosppsych.2011.12.009","article-title":"Valproate-induced hyperammonemic encephalopathy: an update on risk factors, clinical correlates and management","volume":"34","author":"Chopra","year":"2012","journal-title":"Gen. Hosp. Psychiatry"},{"issue":"4","key":"10.1016\/j.eplepsyres.2021.106806_bib6","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1378\/chest.06-2940","article-title":"Hyperammonemia in the ICU","volume":"132","author":"Clay","year":"2007","journal-title":"Chest."},{"key":"10.1016\/j.eplepsyres.2021.106806_bib7","unstructured":"Hospira, Inc : Depacon (valproate sodium) for intravenous injection, USP [package insert]. McPherson, KS, Hospira, Inc."},{"issue":"3","key":"10.1016\/j.eplepsyres.2021.106806_bib8","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1177\/0300060517703278","article-title":"L-carnitine supplementation to reverse a patient undergoing chronic valproic acid treatment: a case report","volume":"45","author":"Maldonado","year":"2017","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.eplepsyres.2021.106806_bib9","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2146\/ajhp110049","article-title":"Levocarnitine for valproic acid-induced hyperammonemic encephalopathy","volume":"69","author":"Mock","year":"2012","journal-title":"Am. J. Health-Syst. Pharm."},{"issue":"5","key":"10.1016\/j.eplepsyres.2021.106806_bib10","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0022-3476(82)80320-X","article-title":"Carnitine deficiency and hyperammonemia associated with valproic acid therapy","volume":"101","author":"Ohtani","year":"1982","journal-title":"J. Pediatr."},{"key":"10.1016\/j.eplepsyres.2021.106806_bib11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/2193-1801-2-13","article-title":"Valproic acid-induced hyperammonemic encephalopathy \u2013 a potentially fatal adverse drug reaction","volume":"2","author":"Sousa","year":"2013","journal-title":"Springerplus"},{"key":"10.1016\/j.eplepsyres.2021.106806_bib12","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.eplepsyres.2012.04.001","article-title":"Risk factors for hyperammonemia associated with valproic acid therapy in adult epilepsy patients","volume":"101","author":"Yamamoto","year":"2012","journal-title":"Epilepsy Res."}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121121002618?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121121002618?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:46:50Z","timestamp":1760276810000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121121002618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":12,"alternative-id":["S0920121121002618"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2021.106806","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of levocarnitine, lactulose, and combination therapy for the treatment of valproic acid-induced hyperammonemia in critically ill patients","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2021.106806","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106806"}}